Table 3 Adverse events and mortality for all patients
Warfarin patients (n = 99) | Control group (n = 99) | P-value | |
|---|---|---|---|
Myocardial infarction, n (%) | 1 (1.0) | 0 | 1.0 |
Stroke, n (%) | 0 | 1 (1.0) | 1.0 |
Pulmonary embolism, n (%) | 0 | 0 | |
Deep venous thrombosis, n (%) | 0 | 0 | |
Sepsis, n (%) | 0 | 1 (1.0) | 1.0 |
Pneumonia, n (%) | 6 (6.1) | 10 (10) | 0.4 |
Urinary tract infection, n (%) | 14 (14) | 14 (14) | 1.0 |
Pressure ulcer, n (%) | 10 (10) | 10 (10) | 1.0 |
Any adverse event, n (%) | 27 (27) | 31 (31) | 0.6 |
In-house mortality, n (%) | 5 (5.1) | 2 (2.0) | 0.4 |
30-day mortality, n (%) | 9 (9.1) | 7 (7.1) | 0.8 |
1-year mortality, n (%) | 26 (26) | 26 (26) | 1.0 |